AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Summary

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Vulvar Adenocarcinoma
• PDAC - Pancreatic Ductal Adenocarcinoma
• Gastric Adenocarcinoma
• GEJ Adenocarcinoma
• Cervical Adenocarcinoma
• Cervical Adenosquamous Carcinoma
• Small Cell Carcinoma of Lung
• Colorectal Cancer
• Hormone Receptor Positive Breast Carcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Avacta Life Sciences Ltd

Last updated on ClinicalTrials.gov

October 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites